Cutaneous lesions of the nose
© Sand et al; licensee BioMed Central Ltd. 2010
Received: 1 February 2010
Accepted: 4 June 2010
Published: 4 June 2010
Skin diseases on the nose are seen in a variety of medical disciplines. Dermatologists, otorhinolaryngologists, general practitioners and general plastic and dermatologic surgeons are regularly consulted regarding cutaneous lesions on the nose. This article is the second part of a review series dealing with cutaneous lesions on the head and face, which are frequently seen in daily practice by a dermatologic surgeon. In this review, we focus on those skin diseases on the nose where surgery or laser therapy is considered a possible treatment option or that can be surgically evaluated.
The nose is the central part of the mid-face and has an important functional, aesthetic and psychological role. Nasal respiration, olfaction and phonation are among its most important functional roles. In addition, the aesthetic importance and its impact on the individual psyche have been the subjects of many previous studies [1–3]. For example, when looking at a face, observers spend the largest amount of gaze time on the nose and eyes, underscoring its prominent position in the central face .
Because of this exposed, highly visible localization, lesions on the skin of the nose are often noticed by patients themselves, typically very early in the course of the disease. The exposed localization on the face is also cause for increased exposure to ultraviolet (UV) light, which represents one of the most dangerous strains for the skin in this particular location because it is a proven carcinogen. This accounts for the high incidence of cancerous involvement of the skin of the nose, which has proven to be the most common site for skin cancer on the human body . Furthermore, this has lead to the description of the face as a "sun terrace," referring to the skin of the forehead, ears and nose, because the angle of the skin toward sunlight at these locations is more acute than elsewhere. Consequently, UV light exposure is increased, which also includes exposure to the dangerous UV-B spectrum (290-320 nm), shown to be one of the most potent skin carcinogens. Typical UV-B-induced DNA damage involves the generation of dimeric photoproducts between adjacent pyrimidine bases. The tumor suppressor gene p53 is a common target of UV-R-induced mutations. Moreover, UV-A generates highly reactive free radicals, damaging DNA and promoting skin cancer. In addition to its role as a potent carcinogen, UV-A is responsible for damage to the collagen structure, leading to accelerated skin aging .
The skin of the nose shows several specific anatomical and histological peculiarities that should be considered when evaluating skin lesions on the nose or when planning the reconstruction of surgical defects . The skin in the areas of the dorsum, columella and sidewalls is thin, loose, compliant and relatively less sebaceous [8, 9]. The skin in the areas of the nasal tip and alae is thicker, more sebaceous, more adherent and less flexible . Surgical procedures on the skin of the nose have to respect these different qualities and the nasal topography, including the nasal aesthetic subunits, to achieve the best possible result. The different aesthetic subunits are the tip subunit, columella subunit, dorsal subunit, right and left alar base subunits, right and left alar side wall subunits and right and left dorsal side wall subunits . The anatomical nasal subunits include the dorsum, sidewalls, lobule, soft triangles, alae and columella. The concept of subunits of the external tissue of the nose has proven useful for planning reconstruction. If more than 50% of the subunit is lost it is favorable to replace the whole subunit with regional tissue or a transplant from a donor site . The most important skin diseases on the nose that can require surgical consultation or successfully undergo laser therapy are described below. The description of all dermatoses that can involve the nose would extend beyond the scope of this review. Therefore, our description is limited to those calling for laser or surgical therapy and to those that are clinically most important in the daily practice of a dermatologic surgeon.
Non-malignant tumors of the nose
A variety of benign skin tumors of the nose are part of daily practice in dermatologic surgery. Such conditions present with different peculiarities and causes. Causes for development of non-malignant tumors of the nose range from simple histomorphologic characteristics, such as the high concentration of sebaceous glands and increased UV-light exposure to more complex genetic abnormalities such as mutations, which can lead to the conditions described briefly below.
Fibrous papule of the nose (syn.: benign solitary fibrous papule, fibrous papule of the face)
Adenoma sebaceum (syn.: Pringle disease)
Hydrocystoma (syn.: cysts of Moll, sudoriferous cysts)
Sebaceous hyperplasia (syn.: sebaceous gland hyperplasia, senile sebaceous hyperplasia)
Sebaceous hyperplasia is the most frequent benign adnexal tumor displaying sebaceous gland differentiation. Men are more frequently affected than woman. Immunosuppressive therapy (e.g., cyclosporin) can trigger its formation . It is almost always located on the face, including the nose, forehead and lateral cheek parts. Clinically, it appears as a whitish-yellow or skin-colored papule that varies in size (2-6 mm) with often accompanying seborrhoea oleosa and telangiectasias. A central umbilication (from which a small globule of sebum is sometimes expressed) is the most important clinically diagnostic feature for differentiating between BCC and sebaceous hyperplasia . Although it is a completely benign lesion and does not require treatment, it can sometimes be cosmetically disturbing or clinically resemble BCC; therefore, a biopsy might be necessary in some cases. Therapy consists of photodynamic therapy, topical trichloroacetic acid, laser treatment (pulsed-dye or CO2 laser), electrosurgery, shave excision, excision or oral isotretinoin therapy for multiple widespread disfiguring sebaceous hyperplasia [41–46].
Melanocytic papillomatous nevi
Melanocytic papillomatous nevi are acquired dermal nevi that are very common. They protrude from the skin surface and may be pigmented or skin-colored. Upon histological examination, they exhibit nevus cell nests in the dermis. Women are more frequently affected than man (9:1), and the nevi are mostly located on the face . Estrogens might influence the pathogenesis of these distinctive melanocytic nevi . Because the major challenge is to exclude malignancy, histology should not be disregarded in cases of clinical doubt regarding the diagnosis. Therapy consists of excision, shave excision or CO2 and erbium: YAG or ruby lasers in cases of a firm clinical diagnosis by an experienced dermatologist.
Freckles (syn.: Ephelides)
Freckles are small brown macules that are very common, mostly on the face and nose of fair-skinned and red- or blond-haired individuals. They are usually multiple, show no correlation with age and can occur at every age . Histological examination reveals no increase in the concentration of melanocytes. UV light results in larger melanosomes, similar to the melanosomes of dark-skinned individuals . Freckles are not associated with increased mortality but may sometimes represent cosmetic problems for some patients. Therapy consists of sun protection, IPL or Q-switched alexandrite laser treatment [61, 62].
Vascular tumors of the nose
The recent WHO classification of cutaneous vascular tumors differentiates between benign vascular tumors, intermediate vascular tumors, tumors of lymph vessels and tumors of perivascular cells. However, 53 different cutaneous vascular tumors have been described in this classification . Because the face and scalp are common locations, the nose is also often affected by vascular tumors of different origins. The most frequent are described below.
Different therapies such as topical, systemic or intra-lesional applications of steroid, alpha 2a and 2b interferon injections, cytotoxic medications, angiogenesis inhibitors, embolization, cryosurgery, laser therapy and conventional surgery have all been described [72, 73]. Imiquimod has also recently been described for the treatment of severe complicated hemangiomas. However, side effects and the small study size make further studies necessary in order to assess this therapeutic option . Recently, Leaute-Labreze and colleagues have achieved impressive results by treating severe fetal hemangiomas of the face with systemic application of the beta-blocker propranolol . After treatment with propranolol administered orally at 2 to 3 mg/kg per day, the authors observed a consistent, rapid, therapeutic effect, leading to a considerable shortening of the natural course of infantile hemangiomas with good clinical tolerance and a low rate of side effects. Initially described in a case report, this has recently been confirmed in larger studies (> 100 patients) [76, 77].
Telangiectasias on the nose are extremely common vascular lesions consisting of dilated blood vessels with a linear appearance. They measure between 0.5 and 1 mm in diameter and can be associated with conditions such as rosacea, scleroderma, dermatomyositis, radiation dermatitis, chronic alcoholism, pregnancy, childhood and Osler-Rendu-Weber disease or be idiopathic (as is true in most cases) . When they appear in abundance, telangiectasias on the nose can hint toward heavy liver illnesses or carcinoid syndrome. Although very rare, there are also a group of hereditary telangiectatic syndromes that should be considered when telangiectasias appear in large numbers and during early childhood. These include Rothmund-Thomson syndrome, Bloom syndrome, Cockayne syndrome, ataxia-telangiectasia and hereditary hemorrhagic telangiectasia [79–85]. Former therapy options included needle diathermy occlusion and polidocanol sclerotherapy. However, modern laser treatment has emerged as the first-line therapy for telangiectasias on the face. Good results have been achieved with PDL, long pulsed KTP-Nd: YAG laser and IPL treatment [86, 87].
Spider nevus (syn.: nevus arachnoides, eppinger star, spider angioma, angioma stellatum)
Osler-Weber-Rendu disease (syn.: hereditary hemorrhagic telangiectasia (HHT))
The following paragraph describes the most frequent inflammatory conditions on the nose.
A variety of topical, systemic and physical treatment options are available that have been adjusted to the stage and severity of the disease . Standard topical therapy includes metronidazole 0.75% or 1% gel. Alternatively, azelaic acid 15% gel or 20% cream has also been successfully used in five randomized and controlled studies with good results . Systemic therapy with doxycycline, minocycline, clarithromycin, and moderately high doses of prednisolone or oral isotretinoin has also been described. Persistent erythema and telangiectasia might respond to pulsed dye laser (PDL) and intense pulsed light (IPL) treatments . Furthermore, it is important to remember that ocular rosacea is a potentially blinding eye disorder common in patients with rosacea (6-18% of rosacea patients) . The main symptom is conjunctival injection, which is sometimes accompanied by chalazion or episcleritis. Rosacea patients should therefore be seen by an ophthalmologist early in the disease course .
Facial eosinophilic granuloma (syn.: granuloma faciale, granuloma eosinophilicum faciale)
Pre-malignant tumors of the nose
Actinic keratoses (syn: solar keratosis, senile keratosis)
Located on the nose, face, scalp, forearms and back of the hand, this very common pre-malignant lesion consists of crusty, scaly patches of skin. Size ranges from 2 - 10 mm, and colors such as pink, red or the same degree of pigmentation as the surrounding skin are observed. Actinic keratoses are associated with UV light exposure and therefore accompanied by solar damage to the surrounding skin. Patients are in or past middle age, very often with fair complexion. Histologically, five types can be distinguished: hypertrophic, atrophic, bowenoid, acantholytic and pigmented . Left untreated this lesion can potentially result in squamous cell carcinoma. Approximately 20% of untreated actinic keratoses result in squamous cell carcinoma . Therapy consists of simple curettage, topical photodynamic therapy, topical imiquimod, topical 3% diclofenac gel or 5-fluorouracil-creme. In case of surgical excision, histologic examination should be performed to exclude squamous cell carcinoma.
Keratoacanthoma (syn.: molluscum sebaceum, molluscum pseudocarcinomatosum, idiopathic cutaneous pseudoepitheliomatous hyperplasia)
First described in 1889 by Hutchinson as a "crateriform ulcer of the face", keratoacanthoma is a fast-growing, epithelial tumor that develops from hair follicles or the surface epithelium of the skin. It can occur solitarily (frequent) or with multiple lesions (rare). The lesion consists of a firm, cone-shaped nodule (1-3 cm in diameter) with a central horn-filled crater. It shows rapid growth within weeks or months followed by spontaneous resolution over 4-6 months in most cases. Histologically and clinically it often resembles SCC. There is debate about whether it undergoes transformation into SCC or is SCC from the beginning [108, 109]. Nevertheless, as SCC can masquerade as keratoacanthoma, surgical excision with an excision margin of 2-3 mm is recommended . Because the histologic changes at the base of the lesion are important for histologic differentiation, a shave biopsy should be avoided and an excision of the lesion in its entirety should be performed . Immunocompromised patients and those with Muir-Torre syndrome (the combined occurrence of at least one sebaceous skin tumor and one internal malignancy in the same patient) show an increased incidence of keratoacanthoma [111, 112].
Malignant tumors of the nose
The skin of the nose is a very common location for malignant tumors. UV-light exposure is a potent carcinogen of the skin, which results in frequent tumor involvement of the skin of the nose. In the following paragraph we present the most frequent malignant skin tumors of the nose.
Unfortunately, there are only a few studies dealing specifically with melanoma on the nose. Jahn et al. have published the largest series of malignant melanomas on the nose so far . In their group of 45 patients, they showed a female predisposition of 64.4%, with lentigo maligna melanoma (LMM) being the most frequent subtype (73.3%). In another study by Fisher et al., 36 patients with melanomas of the nose were described, whereas superficially spreading melanomas were reported in 47% and LMM in 25% of cases . Forty-five percent of these cases were observed in female patients.
Therapy involves surgical excision by cold steel, similar to the procedure performed for cutaneous melanomas at other locations on the body. The recommended standard excision margins published by the American Cancer Society (ACS) and the German Association of Dermato-oncology (ADO) for melanoma of the skin are 10 mm for tumor thickness ≤ 2.00 mm and 20 mm for tumor thickness > 2.00 mm [117, 118]. However, according to the ADO's guideline, in special localizations such as the facial, acral or anogenital regions a reduction of these margins is possible on the condition that micrographic controlled surgery is performed. However, current randomized trial evidence has recently shown to be insufficient in addressing optimal excision margins for primary cutaneous melanomas .
Jahn et al. conclude from their study data that male patients tend to have fewer recurrences than female patients and that LMM has a better prognosis than other histologic subtypes in patients with stage I and II melanoma of the nose . The authors report recurrence rates of 6.7% with all recurrences observed in female patients. The prognoses with stage I and II melanoma of the nose were good, with a survival rate of 97.8% over three years and 95.6% over five years. Unfortunately, there were no data available for patients with stage III melanoma. Jahn et al. further conclude that although tumor thickness is the most important prognostic factor for cutaneous melanoma of the nose, this factor has no significant influence on the prognosis, probably because of the limited number of patients (n = 45). To date all available studies on elective lymph node dissection (ELND) have failed to demonstrate a beneficial effect on patients with cutaneous melanoma of the trunk and extremities; therefore, there is limited evidence to support application of this technique in patients with melanoma of the nose [115, 126–128]. Although a sentinel lymph node biopsy (SLNB) is performed in cutaneous melanomas of other localizations with a tumor thickness > 1.00 mm, the available data for patients with melanomas of the nose do not suggest a clear recommendation regarding prognostic impact. In contrast to the relatively good prognosis for stage I and II melanomas of the skin of the nose, melanoma with sinonasal involvement arising from the nasal cavity and paranasal sinuses is associated with generally poor survival rates . A high rate of local recurrence (31-85%), common distant metastasis (25-50%) and a poor five-year survival rate (13-45%) all make this form of nasal melanoma the most lethal [130–134].
Basal cell carcinoma (Syn.: basalioma, basal cell epithelioma)
Basal cell carcinoma (BCC) is the most common malignancy in humans and accounts for more than 90% of all malignant cutaneous lesions of the head and neck . Because UV light associated with chronic sun exposure is the main risk factor, BCC commonly occurs on the face, with the nose being the most frequently affected location and the alae, dorsum and tip being the parts most frequently affected .
A variety of different treatment options such as cryotherapy, photodynamic therapy, application of imiquimod or 5-fluourouracil, electrodessication and radiation therapy have been described. However, micrographic-controlled surgery is the gold standard with the lowest rate of recurrence (1.0-5,6%) [138–144]. The nose, which is part of the so called H-zone of the face, shows the highest rate of recurrence compared with other localizations . Embryonic fusion planes such as the nasolabial fold or the medial canthus can be affected by large BCCs of the nose, possibly contributing to tumor recurrence.
Squamous cell carcinoma (syn.: spinalioma)
Cutaneous squamous cell carcinoma (SCC) accounts for approximately 10% of skin malignancies on the nose. It is more common in men and 70% of cases are located in the head and neck area . It is related to chronic sun exposure and immunosuppression and rarely arises from normal-appearing skin. SCC typically develops on sun-damaged skin or actinic keratoses and less frequently on scars from burns [147, 148]. In patients having undergone renal transplants and immunosuppression, the incidence has been 18 times greater than in healthy individuals . Clinically, SCC presents as an erythematous crusting, sometimes ulcerated, lesion with a red granular base. It shows a tendency to bleed with minimal trauma. The diagnosis and extent of the lesion sometimes necessitate multiple biopsies. When SCC arises in sun-damaged skin, a minority of patients develop metastases (0.5%) . However, in all patients with SCC of the skin, the metastasis is more frequent (2-3%), and most cases are located in the cervical lymph nodes or parotids [151, 152]. The likelihood of metastasis increases with tumors with a diameter of at least 15 mm and a Breslow tumor thickness (vertical) of at least 2 mm . Death occurs in three-quarters of patients with metastasis [153, 154]. The parotid gland is the "metastatic basin" for cutaneous SCC of the head and neck because it drains via lymphatic vessels on the nose, cheek and forehead . In cases of parotid involvement, a parotidectomy with or without a simultaneous neck dissection is the procedure of choice. Clark levels IV or V are associated with a 20% regional metastatic rate. De novo lesions, an increased depth of invasion (beyond 4-5 mm), tumor size (> 2 cm) and desmoplastic SCCs are associated with a higher rate of metastasis. The same is true for adenoid and mucin-producing types, SCCs of the lower lip (metastatic rate 16%), SCCs on burn scars (18%), radiation-induced SCCs (20%) and/or osteomyelitic sinuses (31%) [137, 156–160].
Micrographic-controlled surgery is the treatment of choice. Excision margins of 4 mm and 6 mm have been suggested for lesions less than and greater than 2 cm, respectively . Because there are no large randomized studies regarding excision margins for cutaneous SCCs, these are rough guidelines. The surgeon's experience and judgment in planning surgical treatment is therefore significant for successful treatment . In cases where patients are unable to undergo surgery radiation, therapy has been described as successful with cure rates similar to those obtained with standard surgical excision. Although chemotherapy has not been effective, some studies report that epidermal growth factor receptor (EGFR) inhibitors might be useful adjuncts to surgical treatment [161, 162].
Kaposi's sarcoma (KS)
KS was first described in 1872 by the Hungarian dermatologist Moritz Kaposi and is a carcinoma arising from the endothelial lining of lymphatic tissue . The histology is characteristic and shows an excessive proliferation of spindle cells, slit-like vascular spaces and extravasated erythrocytes. Principally, KS can arise anywhere on the skin or mucosa of the body, including internal organs. The lower extremities of the skin (especially the soles of the feet) and the head and neck are typically involved.
Over 90% of lesions, regardless of the KS type, are associated with DNA virus human herpes virus 8, also called KS-associated herpesvirus (HHV-8 or KSHV), which has been identified as the primary trigger . Concerning therapy, a variety of modalities have been described. Therapeutic options include systemic therapy in HIV-positive patients (HAART), systemic chemotherapy with doxorubicin, conventional radiation therapy, electron beam radiation therapy (EBRT), surgical excision, topical retinoids, cryotherapy, laser therapy and intra-lesional therapy with vincristin, vinblastin or bleomycin [172, 173].
The most important skin diseases of the nose, which might require surgical consultation or laser therapy, have been described briefly in this review. In conclusion, the authors suggest that all disciplines that offer conservative or surgical treatment must be familiar with the special morphology and characteristics of skin diseases of the nose. In the case of complex lesions an interdisciplinary approach that combines dermatology, otolaryngology and surgery can provide optimal care for the patient.
Written informed consent was obtained from the patients/guardians of the patient for publication of this review article and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Andretto Amodeo C: The central role of the nose in the face and the psyche: review of the nose and the psyche. Aesthetic Plast Surg. 2007, 31: 406-410. 10.1007/s00266-006-0241-2.PubMedGoogle Scholar
- Biller JA, Kim DW: A contemporary assessment of facial aesthetic preferences. Arch Facial Plast Surg. 2009, 11: 91-97. 10.1001/archfacial.2008.543.PubMedGoogle Scholar
- Cellerino A: Psychobiology of facial attractiveness. J Endocrinol Invest. 2003, 26: 45-48.PubMedGoogle Scholar
- Cook JL: Nasal reconstruction. Flaps and grafts in dermatologic surgery. 2008, New York, NY: Elsevier, 191-215.Google Scholar
- Conte CC, Razack MS, Sako K: Skin cancer of the nose: options for reconstruction. J Surg Oncol. 1988, 39: 1-7. 10.1002/jso.2930390102.PubMedGoogle Scholar
- Sjerobabski Masnec I, Poduje S: Photoaging. Coll Antropol. 2008, 32: 177-180.PubMedGoogle Scholar
- Heidari Z, Mahmoudzadeh-Sagheb H, Khammar T, Khammar M: Anthropometric measurements of the external nose in 18-25-year-old Sistani and Baluch aborigine women in the southeast of Iran. Folia Morphol (Warsz). 2009, 68: 88-92.Google Scholar
- Burget GC, Menick FJ: Repair of small surface defects. Aesthetic reconstruction of the nose. Edited by: Burget GC, Menick FJ. 1994, St. Louis, MO: Mosby, 117-156.Google Scholar
- Burget GC, Menick FJ: Aesthetics, visual perception, and surgical judgment. Aesthetic reconstruction of the nose. Edited by: Burget GC, Menick FJ. 1994, St. Louis, MO: Mosby, 1-55.Google Scholar
- Fattahi TT: An overview of facial aesthetic units. J Oral Maxillofac Surg. 2003, 61: 1207-1211. 10.1016/S0278-2391(03)00684-0.PubMedGoogle Scholar
- Chang EW, Nguyen CT: Nose anatomy. [http://emedicine.medscape.com/article/835134-overview]
- Ingham E, Eady A, Goodwin CE, Cove JH, Cunliffe WJ: Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol. 1992, 98: 895-901. 10.1111/1523-1747.ep12460324.PubMedGoogle Scholar
- Guy R, Green MR, Kealey T: Modelling acne in vitro. J Invest Dermatol. 1996, 106: 176-182. 10.1111/1523-1747.ep12329907.PubMedGoogle Scholar
- Stewart ME, Greenwood R, Cunliffe WJ, Strauss JS, Downing DT: Effect of cyproterone acetate-ethinyl estradiol treatment on the proportion of linoleic and sebaceic acids in various skin surface lipid classes. Arch Dermatol Res. 1986, 278: 481-485. 10.1007/BF00455168.PubMedGoogle Scholar
- Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJ: Localisation of androgen receptors in human skin by immunocytochemistry. J Endocrinol. 1992, 133: 467-74. 10.1677/joe.0.1330467.PubMedGoogle Scholar
- Bluefarb SM: Comedos following roentgen ray therapy. Arch Dermatol Syph. 1947, 56: 537-539.Google Scholar
- Trunnell TN, Baer RL, Michaelides P: Acneiform changes in areas of cobalt irradiation. Arch Dermatol. 1972, 106: 73-75. 10.1001/archderm.106.1.73.PubMedGoogle Scholar
- Walter JF: Cobalt radiation-induced comedones. Arch Dermatol. 1980, 116: 1073-1074. 10.1001/archderm.116.9.1073.PubMedGoogle Scholar
- Friedman SJ, Su WPD: Favre-Racouchot syndrome associated with radiation therapy. Cutis. 1983, 31: 306-310.PubMedGoogle Scholar
- Hepburn NC, Crellin RP, Beveridge GW, Rodger A, Tidman MJ: Localized acne as a complication of megavoltage radiotherapy. J Dermatol Treat. 1992, 3: 137-138. 10.3109/09546639209088708.Google Scholar
- Martin WM, Bardsley AF: The comedo skin reaction to radiotherapy. Br J Radiol. 2002, 75: 478-81.PubMedGoogle Scholar
- Gollnick HP, Krautheim A: Topical treatment in acne: current status and future aspects. Dermatology. 2003, 206: 29-36. 10.1159/000067820.PubMedGoogle Scholar
- Nemeth AJ, Penneys NS, Bernstein HB: Fibrous papule: a tumor of fibrohistiocytic cells that contain factor XIIIa. J Am Acad Dermatol. 1988, 19: 1102-6. 10.1016/S0190-9622(88)70279-0.PubMedGoogle Scholar
- Park HS, Cho S, Kim KH, Won CH: Fibrous papule of the face, clear cell type: a case report. J Eur Acad Dermatol Venereol. 2007, 21 (9): 1267-8.PubMedGoogle Scholar
- Lee AN, Stein SL, Cohen LM: Clear cell fibrous papule with NKI/C3 expression: clinical and histologic features in six cases. Am J Dermatopathol. 2005, 27: 296-300. 10.1097/01.dad.0000171608.01552.77.PubMedGoogle Scholar
- Bansal C, Stewart D, Li A, Cockerell CJ: Histologic variants of fibrous papule. J Cutan Pathol. 2005, 32: 424-428. 10.1111/j.0303-6987.2005.00362.x.PubMedGoogle Scholar
- Kucher C, McNiff JM: Epithelioid fibrous papule - a new variant. J Cutan Pathol. 2007, 34: 571-575. 10.1111/j.1600-0560.2006.00667.x.PubMedGoogle Scholar
- Ghosh SK, Bandyopadhyay D, Chatterjee G, Ghosh A, Sarkar S, Sarkar S: Mucocutaneous changes in tuberous sclerosis complex: A clinical profile of 27 Indian patients. Indian J Dermatol. 2009, 54: 255-257. 10.4103/0019-5154.55636.PubMedPubMed CentralGoogle Scholar
- Swaroop MR, Nischal KC, Rajesh Gowda CM, Umashankar NU, Basavaraj HB, Sathyanarayana BD: Radiofrequency ablation of adenoma sebaceum. J Cutan Aesthet Surg. 2008, 1: 89-91. 10.4103/0974-2077.44166.PubMed CentralGoogle Scholar
- Sagar SM, Israel MA: Primary and metastatic tumors of the nervous system. Harrison's Principles Of Internal Medicine. Edited by: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Jameson JL, Longo DL. 2005, NewYork, McGraw-Hill, 2452-61. 16Google Scholar
- Bellack GS, Shapshay SM: Management of facial angiofibromas in tuberous sclerosis with carbon dioxide laser. Otolaryngol Head Neck Surg. 1986, 94: 37-40.PubMedGoogle Scholar
- Anandasabapathy N, Soldano AC: Multiple apocrine hidrocystomas. Dermatology Online Journal. 14: 12-
- Schöpf E, Schulz HJ, Passarge E: Syndrome of cystic eyelids, palmo-plantar keratosis, hypodontia and hypotrichosis as a possible autosomal recessive trait. Birth Defects Orig Artic Ser. 1971, 7: 219-221.PubMedGoogle Scholar
- Dailey RA, Saulny SM, Tower RN: Treatment of multiple apocrine hidrocystomas with trichloracetic acid. Ophthal Plast Reconstr Surg. 2005, 21: 148-150. 10.1097/01.IOP.0000155509.54813.93.PubMedGoogle Scholar
- Echague AV, Astner S, Chen AA, Anderson RR: Multiple apocrine hidrocystoma of the face treated with a 1450-nm diode laser. Arch Dermatol. 2005, 141: 1365-1367. 10.1001/archderm.141.11.1365.PubMedGoogle Scholar
- del Pozo J, García-Silva J, Peña-Penabad C, Fonseca E: Multiple apocrine hidrocystomas:treatment with carbon dioxide laser vaporization. J Dermatol Treat. 2001, 12: 97-10.1080/095466301317085381.Google Scholar
- Gupta S, Handa U, Handa S, Mohan H: The efficacy of electrosurgery and excision in treating patients with multiple apocrine hidrocystomas. Dermatol Surg. 2001, 27: 382-384. 10.1046/j.1524-4725.2001.00210.x.PubMedGoogle Scholar
- Henderer JD, Tanenbaum M: Excision of multiple eyelid apocrine hidrocystomas via an en-bloc lower eyelid blepharoplasty incision. Ophthalmic Surg Lasers. 2000, 31: 157-161.PubMedGoogle Scholar
- Walther T, Hohenleutner U, Landthaler M: Sebaceous gland hyperplasia as a side effect of cyclosporin A. Treatment with the CO2 laser. Dtsch Med Wochensch. 1998, 123: 798-800. 10.1055/s-2007-1024071.Google Scholar
- Hogan DJ, Jones RW, Mason SH: Sebaceous hyperplasia, treatment & medication. [http://emedicine.medscape.com/article/1059368-treatment]
- Alexiades-Armenakas M: Laser-mediated photodynamic therapy. Clin Dermatol. 2006, 24: 16-25. 10.1016/j.clindermatol.2005.10.027.PubMedGoogle Scholar
- Horio T, Horio O, Miyauchi-Hashimoto H, Ohnuki M, Isei T: Photodynamic therapy of sebaceous hyperplasia with topical 5-aminolaevulinic acid and slide projector. Br J Dermatol. 2003, 148: 1274-1276. 10.1046/j.1365-2133.2003.05360.x.PubMedGoogle Scholar
- Bader RS, Scarborough DA: Surgical pearl: intralesional electrodesiccation of sebaceous hyperplasia. J Am Acad Dermatol. 2000, 42: 127-128. 10.1016/S0190-9622(00)90020-3.PubMedGoogle Scholar
- Rosian R, Goslen JB, Brodell RT: The treatment of benign sebaceous hyperplasia with the topical application of bichloracetic acid. J Dermatol Surg Oncol. 1991, 17: 876-879.PubMedGoogle Scholar
- Aghassi D, Gonzalez E, Anderson RR, Rajadhyaksha M, Gonzalez S: Elucidating the pulsed-dye laser treatment of sebaceous hyperplasia in vivo with real-time confocal scanning laser microscopy. J Am Acad Dermatol. 2000, 43: 49-53. 10.1067/mjd.2000.105566.PubMedGoogle Scholar
- Grimalt R, Ferrando J, Mascaro JM: Premature familial sebaceous hyperplasia: successful response to oral isotretinoin in three patients. J Am Acad Dermatol. 1997, 37: 996-998. 10.1016/S0190-9622(97)70082-3.PubMedGoogle Scholar
- Hammes S, Raulin C, Karsai S, Bernt R, Ockenfels HM: Treating papillomatous intradermal nevi: lasers - yes or no? A prospective study. Hautarzt. 2008, 59: 101-107. 10.1007/s00105-007-1464-0.PubMedGoogle Scholar
- Morgan MB, Raley BA, Vannarath RL, Lightfoot SL, Everett MA: Papillomatous melanocytic nevi: an estrogen related phenomenon. J Cutan Pathol. 1995, 22: 446-449. 10.1111/j.1600-0560.1995.tb00761.x.PubMedGoogle Scholar
- Kilty S, Brownrigg P: Surgical treatment of rhinophyma. J Otolaryngol Head Neck Surg. 2008, 37: 269-272.PubMedGoogle Scholar
- Sadick H, Goepel B, Bersch C, Goessler U, Hoermann K, Riedel F: Rhinophyma:diagnosis andtreatment options for a disfiguring tumor of the nose. Ann Plast Surg. 2008, 61: 114-120. 10.1097/SAP.0b013e31815f12d2.PubMedGoogle Scholar
- Aloi F, Tomasini C, Soro E, Pippione M: The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol. 2000, 42: 468-472. 10.1016/S0190-9622(00)90220-2.PubMedGoogle Scholar
- Curnier A, Choudhary S: Rhinophyma: dispelling the myths. Plast Reconstr Surg. 2004, 114: 351-354. 10.1097/01.PRS.0000131875.67987.69.PubMedGoogle Scholar
- Hoffmann M, Braun-Falco M: Rhinophyma-like sebaceous carcinoma. J Eur Acad Dermatol Venereol. 2009, 23: 1216-1218. 10.1111/j.1468-3083.2009.03127.x.PubMedGoogle Scholar
- Aguila LI, Sánchez JL: Angiosarcoma of the face resembling rhinophyma. J Am Acad Dermatol. 2003, 49: 530-531. 10.1067/S0190-9622(03)00742-4.PubMedGoogle Scholar
- Lutz ME, Otley CC: Rhinophyma and coexisting occult skin cancers. Dermatol Surg. 2001, 27: 201-202. 10.1046/j.1524-4725.2001.00251.x.PubMedGoogle Scholar
- Leyngold M, Leyngold I, Letourneau PR, Zamboni WA, Shah H: Basal cell carcinoma and rhinophyma. Ann Plast Surg. 2008, 61: 410-412. 10.1097/SAP.0b013e31816cad18.PubMedGoogle Scholar
- Kempiak SJ, Lee PW, Pelle MT: Rhinophyma treated with cryosurgery. Dermatol Surg. 2009, 35: 543-545. 10.1111/j.1524-4725.2009.01080.x.PubMedGoogle Scholar
- Jung H: Rhinophyma: plastic surgery, rehabilitation, and long-term results. Facial Plast Surg. 1998, 14: 255-278. 10.1055/s-2008-1064457.PubMedGoogle Scholar
- Bastiaens M, Hoefnagel J, Westendorp R, Vermeer BJ, Bouwes Bavinck JN: Solar lentigines are strongly related to sun exposure in contrast to ephelides. Pigment Cell Res. 2004, 17: 225-229. 10.1111/j.1600-0749.2004.00131.x.PubMedGoogle Scholar
- Cockerell CJ, Johnson TM, Swanson NA: Melanocytic nevi. J Cutan Med Surg. 1996, 2: 1561-1563.Google Scholar
- Kawada A, Shiraishi H, Asai M, Kameyama H, Sangen Y, Aragane Y, Tezuka T: Clinical improvement of solar lentigines and ephelides with an intense pulsed light source. Dermatol Surg. 2002, 28: 504-508. 10.1046/j.1524-4725.2002.01175.x.PubMedGoogle Scholar
- Wang CC, Sue YM, Yang CH, Chen CK: A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: a randomized, physician-blinded, split-face comparative trial. J Am Acad Dermatol. 2006, 54 (5): 804-10. 10.1016/j.jaad.2006.01.012.PubMedGoogle Scholar
- Fletcher CDM, Unni KK, Mertens F: Pathology and genetics of tumours of soft tissue and bone. 2002, IARC Press, Lyon, France, 156-176.Google Scholar
- Bailey Byron: Head & Neck Surgery - Otolaryngology. 2001, Lippincott Williams & Wilkins, Philadelphia, 1117-1124. 3Google Scholar
- Finn MC, Glowacki J, Mulliken JB: Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg. 1983, 18: 894-900. 10.1016/S0022-3468(83)80043-8.PubMedGoogle Scholar
- Waner M, North PE, Scherer KA, Frieden IJ, Waner A, Mihm MC: The nonrandom distribution of facial hemangiomas. Arch Dermatol. 2003, 139: 869-875. 10.1001/archderm.139.7.869.PubMedGoogle Scholar
- Garzon MC, Huang JT, Enjolras O, Frieden IJ: Vascular malformations: Part I. J Am Acad Dermatol. 2007, 56: 353-370. 10.1016/j.jaad.2006.05.069.PubMedGoogle Scholar
- Garzon MC, Huang JT, Enjolras O, Frieden IJ: Vascular malformations. Part II: associated syndromes. J Am Acad Dermatol. 2007, 56: 541-564. 10.1016/j.jaad.2006.05.066.PubMedGoogle Scholar
- Waner M, Kastenbaum J, Scherer K: Hemangiomas of the nose. Arch Facial Plast Surg. 2008, 10: 329-334. 10.1001/archfaci.10.5.329.PubMedGoogle Scholar
- Frank J: Genodermatosen, Chapter 11.5 Vaskuläre und lymphatische Erkrankungen. 3. Dermatologie Update Seminar, 13th-14th. 2009, 12-13. November , Wiesbaden GermanyGoogle Scholar
- Cho S, Lee SY, Choi JH, Sung KJ, Moon KC, Koh JK: Treatment of "Cyrano" angioma with pulsed dye laser. Dermatol Surg. 2001, 27: 670-672. 10.1046/j.1524-4725.2001.01009.x.PubMedGoogle Scholar
- Musumeci ML, Schlecht K, Perrotta R, Schwartz RA, Micali G: Management of cutaneous hemangiomas in pediatric patients. Cutis. 2008, 81: 315-322.PubMedGoogle Scholar
- Stier MF, Glick SA, Hirsch R: Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas. J Am Acad Dermatol. 2008, 58: 261-285. 10.1016/j.jaad.2007.10.492.PubMedGoogle Scholar
- Barry RB, Hughes BR, Cook LJ: Involution of infantile haemangiomas after imiquimod 5% cream. Clin Exp Dermatol. 2008, 33: 446-449. 10.1111/j.1365-2230.2007.02676.x.PubMedGoogle Scholar
- Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A: Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008, 358: 2649-2651. 10.1056/NEJMc0708819.PubMedGoogle Scholar
- Sans V, Dumas de la Roque E, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, Lipsker D, Dupuis E, Ezzedine K, Vergnes P, Taïeb A, Léauté-Labrèze C: Propranolol for Severe Infantile Hemangiomas: Follow-Up Report. Pediatrics. 2009,Google Scholar
- Löffler H, Kosel C, Cremer H, Kachel W: Propanolol therapy to treat problematic hemangiomas. A new standard therapy makes its debut. Hautarzt. 2009, 60: 1013-1016. 10.1007/s00105-009-1856-4.PubMedGoogle Scholar
- Bailey Byron: Head & Neck Surgery - Otolaryngology. 2001, Lippincott Williams & Wilkins, Philadelphia, 2438-3Google Scholar
- Stinco G, Governatori G, Mattighello P, Patrone P: Multiple cutaneous neoplasms in a patient with Rothmund-Thomson syndrome: case report and published work review. J Dermatol. 2008, 35: 154-161. 10.1111/j.1346-8138.2008.00436.x.PubMedGoogle Scholar
- Moss C: "New" syndrome with telangiectasia, dwarfism, and spondyloepiphyseal dysplasia may be Rothmund-Thomson syndrome. Pediatr Dermatol. 1990, 7: 82-84. 10.1111/j.1525-1470.1990.tb01084.x.PubMedGoogle Scholar
- Kaneko H, Kondo N: Clinical features of Bloom syndrome and function of the causative gene, BLM helicase. Expert Rev Mol Diagn. 2004, 4: 393-401. 10.1586/1473722.214.171.1243.PubMedGoogle Scholar
- Cantani A, Bamonte G, Bellioni P, Tucci Bamonte M, Ceccoli D, Tacconi ML: Rare syndromes. I. Cockayne syndrome: a review of the 129 cases so far reported in the literature. Riv Eur Sci Med Farmacol. 1987, 9: 9-17.PubMedGoogle Scholar
- Nance MA, Berry SA: Cockayne syndrome: review of 140 cases. Am J Med Genet. 1992, 42: 68-84. 10.1002/ajmg.1320420115.PubMedGoogle Scholar
- Bergler W, Götte K: Hereditary hemorrhagic telangiectasias: a challenge for the clinician. Eur Arch Otorhinolaryngol. 1999, 256: 10-15. 10.1007/s004050050114.PubMedGoogle Scholar
- Spacey SD, Gatti RA, Bebb G: The molecular basis and clinical management of ataxia telangiectasia. Can J Neurol Sci. 2000, 27: 184-191.PubMedGoogle Scholar
- Werner A, Bäumler W, Zietz S, Kühnel T, Hohenleutner U, Landthaler M: Hereditary haemorrhagic telangiectasia treated by pulsed neodymium:yttrium-aluminium-garnet (Nd:YAG) laser (1,064 nm). Lasers Med Sci. 2008, 23: 385-391. 10.1007/s10103-007-0512-4.PubMedGoogle Scholar
- Mahoney EJ, Shapshay SM: New classification of nasal vasculature patterns in hereditary hemorrhagic telangiectasia. Am J Rhinol. 2006, 20: 87-90.PubMedGoogle Scholar
- Hellwig S, Petzoldt D, Raulin C: The pulsed dye laser--possibilities and limits. Hautarzt. 1997, 48: 536-40. 10.1007/s001050050624.PubMedGoogle Scholar
- Harrison DF: Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope. 1982, 92: 314-320. 10.1288/00005537-198203000-00017.PubMedGoogle Scholar
- Shah RK, Dhingra JK, Shapshay SM: Hereditary hemorrhagic telangiectasia: a review of 76 cases. Laryngoscope. 2002, 112: 767-773. 10.1097/00005537-200205000-00001.PubMedGoogle Scholar
- Del Rosso JQ: Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006, 78: 97-100.PubMedGoogle Scholar
- Rebora A: Rosacea. J Invest Dermatol. 1987, 88: 56-60. 10.1111/1523-1747.ep12468949.Google Scholar
- Berg M, Lidén S: An epidemiological study of rosacea. Acta Derm Venereol. 1989, 69: 419-423.PubMedGoogle Scholar
- Elsaie ML, Choudhary S: Updates on the pathophysiology and management of acne rosacea. Postgrad Med. 2009, 121: 178-186. 10.3810/pgm.2009.09.2066.PubMedGoogle Scholar
- Yamasaki K, Di Nardo A, Bardan A, Murakami M, Takaaki O, Coda A, Dorschner RA, Bonnart C, Descargues P, Hovnanian A, Morhenn VB, Gallo RL: Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007, 13: 975-80. 10.1038/nm1616.PubMedGoogle Scholar
- Rebora A: The management of rosacea. Am J Clin Dermatol. 2002, 3: 489-496. 10.2165/00128071-200203070-00005.PubMedGoogle Scholar
- Korting HC, Schöllmann C: Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009, 23: 876-882. 10.1111/j.1468-3083.2009.03167.x.PubMedGoogle Scholar
- Neuhaus IM, Zane LT, Tope WD: Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg. 2009, 35: 920-928. 10.1111/j.1524-4725.2009.01156.x.PubMedGoogle Scholar
- Stone DU, Chodosh J: Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol. 2004, 15: 499-502. 10.1097/01.icu.0000143683.14738.76.PubMedGoogle Scholar
- Eiseman AS: The ocular manifestations of atopic dermatitis and rosacea. Curr Allergy Asthma Rep. 2006, 6: 292-298. 10.1007/s11882-006-0062-z.PubMedGoogle Scholar
- Wigley JEM: Sarcoid of Boeck? Eosinophilic granuloma. Br J Dermatol. 1945, 57: 68-69. 10.1111/j.1365-2133.1945.tb11202.x.Google Scholar
- Rieker J, Hengge U, Ruzicka T, Bruch-Gerharz D: Multifocal facial eosinophilic granuloma: successful treatment with topical tacrolimus. Hautarzt. 2006, 57: 324-326. 10.1007/s00105-006-1112-0.PubMedGoogle Scholar
- Chensue SW, Warmington K, Ruth J, Lincoln P, Kuo MC, Kunkel SL: Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Am J Path. 1994, 145: 1105-1113.PubMedPubMed CentralGoogle Scholar
- Besnier E: Lupus pernio de la face; synovites fongueuses (scrofulo-tuberculeuses) symétriques des extrémités superieures. Annales de dermatologie et de syphilographie. 1889, 10: 333-336.Google Scholar
- Badgwell C, Rosen T: Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol. 2007, 56: 69-83. 10.1016/j.jaad.2006.06.019.PubMedGoogle Scholar
- Kirkham N: Tumors and cysts of the Epidermis. Lever, Histopathology of the skin. 2009, Lippincott Williams & Wilkins, Philadelphia USA, 791-849. 10Google Scholar
- Montgomery H, Dörffel J: Verruca senilis und keratoma senile. Arch Dermatol Syph. 1932, 166: 286-10.1007/BF02069898.Google Scholar
- Rook A, Whimster I: Keratoacanthoma--a thirty year retrospect. Br J Dermatol. 1979, 100: 41-47. 10.1111/j.1365-2133.1979.tb03568.x.PubMedGoogle Scholar
- Belisario JC: Brief review of keratoacanthomas and description of keratoacanthoma centrifugum marginatum, another variety of keratoacanthoma. Aust J Dermatol. 1965, 8: 65-72. 10.1111/j.1440-0960.1965.tb01715.x.PubMedGoogle Scholar
- Popkin GL, Brodie SJ, Hyman AB, Andrade R, Kopf AW: A technique of biopsy recommended for keratoacanthoma. Arch Dermatol. 1966, 94: 191-193. 10.1001/archderm.94.2.191.PubMedGoogle Scholar
- Sullivan JJ, Colditz GA: Keratoacanthoma in a subtropical climate. Australas J Dermatol. 1979, 20: 34-40. 10.1111/j.1440-0960.1979.tb00122.x.PubMedGoogle Scholar
- Muir EG, Bell AJ, Barlow KA: Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg. 1967, 54: 191-195. 10.1002/bjs.1800540309.PubMedGoogle Scholar
- Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001, 94: 153-156. 10.1002/ijc.1440.PubMedGoogle Scholar
- Garbe C, Leiter U: Melanoma epidemiology and trends. Clin Dermatol. 2009, 27: 3-9. 10.1016/j.clindermatol.2008.09.001.PubMedGoogle Scholar
- Jahn V, Breuninger H, Garbe C, Maassen M, Moehrle M: Melanoma of the Nose: Prognostic Factors, Three-Dimensional Histology, and Surgical Strategies. Laryngoscope. 2006, 116: 1204-1211. 10.1097/01.mlg.0000224344.19828.be.PubMedGoogle Scholar
- Fisher SR: Cutaneous malignant melanoma of the head and neck. Laryngoscope. 1989, 99: 822-836. 10.1288/00005537-198908000-00010.PubMedGoogle Scholar
- Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R: Leitlinie malignes Melanom Vers 15. [http://www.ado-homepage.de/projekte/1/upload/leitlinie_melanom_ado_2005.pdf]
- American Cancer Society (ACS): Treatment of Melanoma by Stage. [http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=39]
- Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, Hollis S, Lens MB, Thompson JF: Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009, 4: CD004835-PubMedGoogle Scholar
- Gambichler T, Moussa G, Bahrenberg K, Vogt M, Ermert H, Weyhe D, Altmeyer P, Hoffmann K: Preoperative ultrasonic assessment of thin melanocytic skin lesions using a 100-MHz ultrasound transducer: a comparative study. Dermatol Surg. 2007, 33: 818-824. 10.1111/j.1524-4725.2007.33175.x.PubMedGoogle Scholar
- Vilana R, Puig S, Sanchez M, Squarcia M, Lopez A, Castel T, Malvehy J: Preoperative assessment of cutaneous melanoma thickness using 10-MHz sonography. AJR Am J Roentgenol. 2009, 193: 639-43. 10.2214/AJR.08.1387.PubMedGoogle Scholar
- Temple CL, Arlette JP: Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol. 2006, 94: 287-92. 10.1002/jso.20305.PubMedGoogle Scholar
- Mohs FE, Snow SN, Larson PO: Mohs micrographic surgery fixed-tissue technique for melanoma of the nose. J Dermatol Surg Oncol. 1990, 16: 1111-1120.PubMedGoogle Scholar
- Leitlinien der Deutschen Dermatologischen Gesellschaft (DDG): Mikroskopisch kontrollierte Chirurgie (MKC). [http://www.uni-duesseldorf.de/AWMF/ll/013-064.htm]
- Maloney ME: Determining Cancer at Surgical margin. Surgical Dermatopathology. 1999, Cambridge, MA: Blackwell Publishers, 113-116.Google Scholar
- Veronesi U, Adamus J, Bandiera DC: Inaffeciacy of immediate node dissection in stage 1 melanoma of the limbs. N Eng J Med. 1977, 297: 627-630. 10.1056/NEJM197709222971202.Google Scholar
- Cascinelli N, Morabito A, Santinami M: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998, 351: 793-796. 10.1016/S0140-6736(97)08260-3.PubMedGoogle Scholar
- Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, Barnhill RL, Wanebo HJ: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996, 224: 255-263. 10.1097/00000658-199609000-00002.PubMedPubMed CentralGoogle Scholar
- Dauer EH, Lewis JE, Rohlinger AL, Weaver AL, Olsen KD: Sinonasal melanoma: A clinicopathological review of 61 cases. Otolaryngol Head Neck Surg. 2008, 138: 347-52. 10.1016/j.otohns.2007.12.013.PubMedGoogle Scholar
- Loree TR, Mullins AP, Spellman J, North JH, Hicks WL: Head and neck mucosal melanoma: a 32-year review. Ear Nose Throat J. 1999, 78: 372-375.PubMedGoogle Scholar
- Pandey M, Abraham EK, Mathew A, Ahamed IM: Primary malignant melanoma of the upper aero-digestive tract. Int J Oral Maxillofac Surg. 1999, 28: 45-49. 10.1016/S0901-5027(99)80676-6.PubMedGoogle Scholar
- Mendenhall WM, Amdur RJ, Hinermann RW, Werning JW, Villaret B, Mendenhall , Price Nancy: Head and neck mucosal melanoma. Am J Clin Oncol. 2005, 28: 626-630. 10.1097/01.coc.0000170805.14058.d3.PubMedGoogle Scholar
- Sand M, Sand D, Brors D, Altmeyer P, Mann B, Bechara FG: Cutaneous lesions of the external ear. Head Face Med. 2008, 4: 2-10.1186/1746-160X-4-2.PubMedPubMed CentralGoogle Scholar
- Wettstein R, Erba P, Farhadi J, Kalbermatten DF, Arnold A, Haug M, Pierer G: Incomplete excision of basal cell carcinoma in the subunits of the nose. Scand J Plast Reconstr Surg Hand Surg. 2008, 42: 92-95. 10.1080/02844310701694811.PubMedGoogle Scholar
- Sand M, Bechara FG, Sand D, Moussa G, Stücker M, Altmeyer P, Hoffmann K, Rotterdam S: Polyglandular autoimmune syndrome associated with pigmented basal cell carcinoma. J Dermatol. 2005, 32: 1044-1047.PubMedGoogle Scholar
- Jeevankumar B, Thappa DM: Unusual presentation of basal cell carcinoma on face. Indian J Dermatol. 2005, 50: 161-163.Google Scholar
- Kirkam N: Tumors and cysts of the epidermis. Lever's Histopathology of the Skin. Edited by: Elder D, Elenistsas R, Jaworsky C, Johnson B Jr. 1997, Philadelphia: Lippincott-Raven, 685-746. 8Google Scholar
- Rowe DE, Carroll RJ, Day CL: Long-term recurrence rates in previously untreated basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989, 15: 315-328.PubMedGoogle Scholar
- Sand M, Boorboor P, Sand D, Altmeyer P, Mann B, Bechara FG: Bilateral cheek-to-nose advancement flap: an alternative to the paramedian forehead flap for reconstruction of the nose. Acta Chir Plast. 2007, 49: 67-70.PubMedGoogle Scholar
- Rowe DE, Raymond JC, Day CL: Mohs' surgery is the treatment of choice for recurrent basal cell carcinoma. J Dermatol Surg Oncol. 1989, 15: 424-431.PubMedGoogle Scholar
- Barzilai DA, Freiman A, Dellavalle RP, Weinstock MA, Mostow EN: Dermatoepidemiology. J Am Acad Dermatol. 52: 559-573. 10.1016/j.jaad.2004.09.019.
- Wu JK, Siller G, Whitehead K: Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australas J Dermatol. 44: 123-125. 10.1046/j.1440-0960.2003.00658.x.
- Childers BJ, Goldwyn RM, Ramos D, Chaffey J, Harris JR: Long-term results of irradiation for basal cell carcinoma of the skin of the nose. Plast Reconstr Surg. 93: 1169-1173.
- Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol. 2005, 53: 452-457. 10.1016/j.jaad.2005.04.087.PubMedGoogle Scholar
- Swanson NA: Mohs surgery. Technique, indications, applications, and the future. Arch Dermatol. 1983, 119: 761-773. 10.1001/archderm.119.9.761.PubMedGoogle Scholar
- Stucker FJ, Nathan CA, Lian TS: Cutaneous malignancy. Head & Neck Surgery - Otolaryngology. Edited by: Byron J Bailey. 2001, Lippincott Williams & Wilkins, Philadelphia, 1223-1235. 3Google Scholar
- Kirkham N: Tumours and cysts of the epidermis. Lever's histopathology of the skin. Edited by: Lever WF, Lever GS. 1997, Philadelphia: Lippincott-Raven, 685-746. 8Google Scholar
- Bauk VOZ, Assunção AM, Domingues RF, Fernandes NC, Maya TC, Maceira JP: Marjolin's ulcer: a twelve-case report. An Bras Dermatol. 2006, 81: 355-358. 10.1590/S0365-05962006000400008.Google Scholar
- Gupta AK, Cardella CJ, Haberman HF: Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol. 1986, 122: 1288-93. 10.1001/archderm.122.11.1288.PubMedGoogle Scholar
- Lundt HZ: How often does squamous cell carcinoma of the skin metastasize?. Arch Dermatol. 1965, 92: 635-637. 10.1001/archderm.1965.01600180027004.Google Scholar
- Joseph MG, Zulueta WP, Kennedy PJ: Squamous cell carcinoma of the skin. The incidence of metastases and their outcome. ANZ J Surg. 1991, 62: 697-701. 10.1111/j.1445-2197.1992.tb07065.x.Google Scholar
- Czarnecki D, Staples M, Mar A, Giles G, Meehan C: Metastases from squamous cell carcinoma of the skin in Southern Australia. Dermatology. 1994, 189: 52-54. 10.1159/000246783.PubMedGoogle Scholar
- Møller R, Reymann F, Hou-Jensen K: Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol. 1979, 115: 703-705. 10.1001/archderm.115.6.703.PubMedGoogle Scholar
- Epstein E, Epstein NN, Bragg K, Linden G: Metastases from squamous cell carcinomas of the skin. Arch Dermatol. 1968, 97: 245-251. 10.1001/archderm.97.3.245.PubMedGoogle Scholar
- Veness MJ, Porceddu S, Palme CE, Morgan GJ: Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck. 2007, 29: 621-631. 10.1002/hed.20576.PubMedGoogle Scholar
- Frierson HF, Cooper PH: Prognostic factors in squamous cell carcinoma of the lower lip. Hum Pathol. 1986, 17: 346-354. 10.1016/S0046-8177(86)80457-9.PubMedGoogle Scholar
- Arons MS, Lynch JB, Lewis SR, Blocker TG: Scar tissue carcinoma. I. A clinical study with special reference to burn scar carcinoma. Ann Surg. 1965, 161: 170-188. 10.1097/00000658-196502000-00003.PubMedPubMed CentralGoogle Scholar
- Martin H, Strong E, Spiro RH: Radiation-induced skin cancer of the head and neck. Cancer. 1970, 25: 61-71. 10.1002/1097-0142(197001)25:1<61::AID-CNCR2820250110>3.0.CO;2-W.PubMedGoogle Scholar
- Sedlin ED, Fleming JL: Epidermal carcinoma arising in chronic osteomyelitic foci. J Bone Joint Surg. 1963, 45: 827-837.Google Scholar
- Gross MD, Monroe M: Skin cancer: squamous cell carcinoma. [http://emedicine.medscape.com/article/870430-overview]
- Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN: Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges. 2008, 6: 1066-1069. 10.1111/j.1610-0387.2008.06861.x.PubMedGoogle Scholar
- Shimizu T, Izumi H, Oga A, Furumoto H, Murakami T, Ofuji R, Muto M, Sasaki K: Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology. 2001, 202: 203-206. 10.1159/000051637.PubMedGoogle Scholar
- Kaposi M: Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph. 1872, 4: 265-273. 10.1007/BF01830024.Google Scholar
- Masih RB, Jesudass SW, Verghese A: Kaposi's sarcoma of the tip of the nose as a sentinel sign for Kaposi's sarcoma of the lung. Chest. 1996, 110: 576-10.1378/chest.110.2.576.PubMedGoogle Scholar
- Kaloterakis A, Papasteriades C, Filiotou A, Economidou J, Hadjiyannis S, Stratigos J: HLA in familial and nonfamilial Mediterranean Kaposi's sarcoma in Greece. Tissue Antigens. 1995, 45: 117-119. 10.1111/j.1399-0039.1995.tb02427.x.PubMedGoogle Scholar
- Calabrò ML, Sheldon J, Favero A, Simpson GR, Fiore JR, Gomes E, Angarano G, Chieco-Bianchi L, Schulz TF: Seroprevalence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 in several regions of Italy. J Hum Virol. 1998, 1: 207-213.PubMedGoogle Scholar
- Penn I: Cancer in the immunosuppressed organ recipient. Transplant Proc. 1991, 23: 1771-1772.PubMedGoogle Scholar
- Penn I: Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am. 1993, 7: 431-445.PubMedGoogle Scholar
- DeVita V: AIDS-related malignancies. Cancer: Principles and Practice of Clinical Oncology. Edited by: DeVita V, Vincent T Jr. 2008, Philadelphia, Pa: Lippincott, Williams, & Wilkins, 8: 2404-2407. 5Google Scholar
- Rose LJ, Fishman AD, Sparano JA: Kaposi Sarcoma. [http://emedicine.medscape.com/article/279734-overview]
- Jacobson LP, Jenkins FJ, Springer G, Muñoz A, Shah KV, Phair J, Zhang Z, Armenian H: Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma. J Infect Dis. 2000, 181: 1940-1949. 10.1086/315503.PubMedGoogle Scholar
- Nobler MP, Leddy ME, Huh SH: The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome. J Clin Oncol. 1987, 5: 107-112.PubMedGoogle Scholar
- Dezube BJ: Acquired immunodeficiency syndrome-related Kaposi's sarcoma: clinical features, staging, and treatment. Semin Oncol. 2000, 27: 424-430.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.